Intrinsic value of PTC Therapeutics - PTCT

Previous Close

$33.26

  Intrinsic Value

$202.16

stock screener

  Rating & Target

str. buy

+508%

Previous close

$33.26

 
Intrinsic value

$202.16

 
Up/down potential

+508%

 
Rating

str. buy

We calculate the intrinsic value of PTCT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  43.30
  39.47
  36.02
  32.92
  30.13
  27.62
  25.35
  23.32
  21.49
  19.84
  18.35
  17.02
  15.82
  14.74
  13.76
  12.89
  12.10
  11.39
  10.75
  10.17
  9.66
  9.19
  8.77
  8.39
  8.06
  7.75
  7.47
  7.23
  7.00
  6.80
Revenue, $m
  279
  389
  528
  702
  914
  1,167
  1,462
  1,803
  2,191
  2,625
  3,107
  3,636
  4,211
  4,832
  5,497
  6,205
  6,955
  7,747
  8,580
  9,453
  10,366
  11,319
  12,311
  13,345
  14,420
  15,537
  16,699
  17,905
  19,160
  20,463
Variable operating expenses, $m
  139
  189
  252
  331
  427
  541
  675
  829
  1,005
  1,201
  1,406
  1,646
  1,906
  2,187
  2,488
  2,808
  3,148
  3,506
  3,883
  4,278
  4,691
  5,123
  5,572
  6,040
  6,526
  7,032
  7,558
  8,104
  8,671
  9,261
Fixed operating expenses, $m
  180
  184
  188
  192
  196
  201
  205
  209
  214
  219
  224
  229
  234
  239
  244
  249
  255
  260
  266
  272
  278
  284
  290
  297
  303
  310
  317
  324
  331
  338
Total operating expenses, $m
  319
  373
  440
  523
  623
  742
  880
  1,038
  1,219
  1,420
  1,630
  1,875
  2,140
  2,426
  2,732
  3,057
  3,403
  3,766
  4,149
  4,550
  4,969
  5,407
  5,862
  6,337
  6,829
  7,342
  7,875
  8,428
  9,002
  9,599
Operating income, $m
  -41
  16
  88
  179
  291
  425
  582
  764
  972
  1,205
  1,477
  1,762
  2,072
  2,406
  2,765
  3,147
  3,553
  3,981
  4,431
  4,903
  5,396
  5,912
  6,449
  7,008
  7,590
  8,195
  8,824
  9,478
  10,157
  10,864
EBITDA, $m
  -16
  45
  124
  222
  343
  487
  658
  854
  1,078
  1,330
  1,609
  1,916
  2,250
  2,611
  2,998
  3,410
  3,848
  4,309
  4,795
  5,304
  5,836
  6,392
  6,971
  7,574
  8,202
  8,854
  9,532
  10,237
  10,970
  11,731
Interest expense (income), $m
  5
  14
  25
  38
  55
  75
  101
  131
  167
  208
  254
  306
  364
  428
  497
  571
  651
  736
  826
  921
  1,021
  1,126
  1,235
  1,350
  1,469
  1,593
  1,722
  1,856
  1,996
  2,140
  2,291
Earnings before tax, $m
  -55
  -9
  50
  125
  215
  324
  451
  598
  764
  951
  1,171
  1,398
  1,644
  1,910
  2,194
  2,496
  2,817
  3,155
  3,510
  3,882
  4,271
  4,677
  5,099
  5,540
  5,997
  6,473
  6,968
  7,482
  8,017
  8,573
Tax expense, $m
  0
  0
  14
  34
  58
  87
  122
  161
  206
  257
  316
  377
  444
  516
  592
  674
  761
  852
  948
  1,048
  1,153
  1,263
  1,377
  1,496
  1,619
  1,748
  1,881
  2,020
  2,165
  2,315
Net income, $m
  -55
  -9
  37
  91
  157
  236
  329
  436
  558
  694
  855
  1,020
  1,200
  1,394
  1,602
  1,822
  2,056
  2,303
  2,562
  2,834
  3,118
  3,414
  3,723
  4,044
  4,378
  4,726
  5,087
  5,462
  5,852
  6,258

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  405
  566
  769
  1,022
  1,331
  1,698
  2,128
  2,625
  3,189
  3,821
  4,523
  5,293
  6,130
  7,033
  8,001
  9,032
  10,124
  11,277
  12,489
  13,760
  15,089
  16,475
  17,921
  19,425
  20,990
  22,616
  24,307
  26,063
  27,889
  29,786
Adjusted assets (=assets-cash), $m
  405
  566
  769
  1,022
  1,331
  1,698
  2,128
  2,625
  3,189
  3,821
  4,523
  5,293
  6,130
  7,033
  8,001
  9,032
  10,124
  11,277
  12,489
  13,760
  15,089
  16,475
  17,921
  19,425
  20,990
  22,616
  24,307
  26,063
  27,889
  29,786
Revenue / Adjusted assets
  0.689
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
  0.687
Average production assets, $m
  59
  82
  112
  149
  194
  247
  310
  382
  464
  557
  659
  771
  893
  1,024
  1,165
  1,315
  1,475
  1,642
  1,819
  2,004
  2,198
  2,400
  2,610
  2,829
  3,057
  3,294
  3,540
  3,796
  4,062
  4,338
Working capital, $m
  -35
  -49
  -66
  -88
  -114
  -146
  -183
  -225
  -274
  -328
  -388
  -454
  -526
  -604
  -687
  -776
  -869
  -968
  -1,073
  -1,182
  -1,296
  -1,415
  -1,539
  -1,668
  -1,802
  -1,942
  -2,087
  -2,238
  -2,395
  -2,558
Total debt, $m
  248
  381
  551
  761
  1,018
  1,324
  1,683
  2,096
  2,566
  3,093
  3,677
  4,318
  5,016
  5,768
  6,574
  7,433
  8,343
  9,304
  10,313
  11,372
  12,479
  13,634
  14,838
  16,091
  17,394
  18,749
  20,157
  21,620
  23,141
  24,722
Total liabilities, $m
  338
  471
  641
  852
  1,108
  1,414
  1,773
  2,186
  2,656
  3,183
  3,767
  4,409
  5,106
  5,858
  6,665
  7,523
  8,434
  9,394
  10,404
  11,462
  12,569
  13,724
  14,928
  16,181
  17,484
  18,839
  20,247
  21,711
  23,231
  24,812
Total equity, $m
  68
  94
  128
  171
  222
  284
  355
  438
  533
  638
  755
  884
  1,024
  1,174
  1,336
  1,508
  1,691
  1,883
  2,086
  2,298
  2,520
  2,751
  2,993
  3,244
  3,505
  3,777
  4,059
  4,353
  4,657
  4,974
Total liabilities and equity, $m
  406
  565
  769
  1,023
  1,330
  1,698
  2,128
  2,624
  3,189
  3,821
  4,522
  5,293
  6,130
  7,032
  8,001
  9,031
  10,125
  11,277
  12,490
  13,760
  15,089
  16,475
  17,921
  19,425
  20,989
  22,616
  24,306
  26,064
  27,888
  29,786
Debt-to-equity ratio
  3.660
  4.030
  4.290
  4.460
  4.580
  4.670
  4.730
  4.780
  4.820
  4.850
  4.870
  4.890
  4.900
  4.910
  4.920
  4.930
  4.930
  4.940
  4.940
  4.950
  4.950
  4.960
  4.960
  4.960
  4.960
  4.960
  4.970
  4.970
  4.970
  4.970
Adjusted equity ratio
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -55
  -9
  37
  91
  157
  236
  329
  436
  558
  694
  855
  1,020
  1,200
  1,394
  1,602
  1,822
  2,056
  2,303
  2,562
  2,834
  3,118
  3,414
  3,723
  4,044
  4,378
  4,726
  5,087
  5,462
  5,852
  6,258
Depreciation, amort., depletion, $m
  25
  30
  36
  43
  52
  63
  75
  90
  106
  125
  132
  154
  179
  205
  233
  263
  295
  328
  364
  401
  440
  480
  522
  566
  611
  659
  708
  759
  812
  868
Funds from operations, $m
  -30
  21
  73
  134
  209
  299
  405
  526
  664
  819
  987
  1,175
  1,379
  1,599
  1,835
  2,085
  2,351
  2,631
  2,926
  3,234
  3,557
  3,894
  4,245
  4,610
  4,990
  5,384
  5,795
  6,221
  6,665
  7,126
Change in working capital, $m
  -11
  -14
  -17
  -22
  -26
  -32
  -37
  -43
  -48
  -54
  -60
  -66
  -72
  -78
  -83
  -89
  -94
  -99
  -104
  -109
  -114
  -119
  -124
  -129
  -134
  -140
  -145
  -151
  -157
  -163
Cash from operations, $m
  -19
  35
  90
  156
  236
  331
  442
  569
  713
  873
  1,047
  1,241
  1,451
  1,676
  1,918
  2,174
  2,445
  2,730
  3,030
  3,344
  3,671
  4,013
  4,369
  4,739
  5,124
  5,524
  5,940
  6,372
  6,822
  7,289
Maintenance CAPEX, $m
  -8
  -12
  -16
  -22
  -30
  -39
  -49
  -62
  -76
  -93
  -111
  -132
  -154
  -179
  -205
  -233
  -263
  -295
  -328
  -364
  -401
  -440
  -480
  -522
  -566
  -611
  -659
  -708
  -759
  -812
New CAPEX, $m
  -18
  -23
  -30
  -37
  -45
  -54
  -63
  -72
  -82
  -92
  -102
  -112
  -122
  -132
  -141
  -150
  -159
  -168
  -177
  -185
  -194
  -202
  -210
  -219
  -228
  -237
  -246
  -256
  -266
  -276
Cash from investing activities, $m
  -26
  -35
  -46
  -59
  -75
  -93
  -112
  -134
  -158
  -185
  -213
  -244
  -276
  -311
  -346
  -383
  -422
  -463
  -505
  -549
  -595
  -642
  -690
  -741
  -794
  -848
  -905
  -964
  -1,025
  -1,088
Free cash flow, $m
  -46
  -1
  44
  97
  161
  239
  329
  434
  554
  688
  833
  997
  1,175
  1,366
  1,572
  1,791
  2,023
  2,268
  2,525
  2,795
  3,077
  3,371
  3,678
  3,998
  4,330
  4,676
  5,035
  5,408
  5,797
  6,200
Issuance/(repayment) of debt, $m
  103
  133
  170
  211
  257
  306
  359
  413
  470
  527
  584
  641
  697
  752
  806
  859
  910
  960
  1,010
  1,058
  1,107
  1,155
  1,204
  1,253
  1,303
  1,355
  1,408
  1,463
  1,521
  1,581
Issuance/(repurchase) of shares, $m
  76
  36
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  179
  169
  170
  211
  257
  306
  359
  413
  470
  527
  584
  641
  697
  752
  806
  859
  910
  960
  1,010
  1,058
  1,107
  1,155
  1,204
  1,253
  1,303
  1,355
  1,408
  1,463
  1,521
  1,581
Total cash flow (excl. dividends), $m
  133
  168
  214
  308
  418
  545
  688
  848
  1,024
  1,215
  1,418
  1,638
  1,872
  2,119
  2,378
  2,650
  2,933
  3,228
  3,535
  3,853
  4,184
  4,527
  4,882
  5,251
  5,634
  6,031
  6,443
  6,872
  7,317
  7,781
Retained Cash Flow (-), $m
  -76
  -36
  -34
  -42
  -51
  -61
  -72
  -83
  -94
  -106
  -117
  -129
  -140
  -151
  -162
  -172
  -182
  -193
  -202
  -212
  -222
  -232
  -241
  -251
  -261
  -272
  -282
  -293
  -305
  -317
Prev. year cash balance distribution, $m
  109
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  166
  133
  180
  265
  366
  483
  616
  765
  930
  1,109
  1,301
  1,509
  1,732
  1,968
  2,216
  2,477
  2,750
  3,035
  3,332
  3,641
  3,962
  4,295
  4,641
  5,000
  5,372
  5,759
  6,161
  6,578
  7,012
  7,464
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  159
  122
  156
  218
  284
  351
  416
  478
  534
  582
  618
  644
  659
  661
  651
  630
  598
  559
  513
  463
  410
  356
  304
  255
  209
  168
  132
  102
  77
  56
Current shareholders' claim on cash, %
  86.1
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7
  81.7

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

FINANCIAL RATIOS  of  PTC Therapeutics (PTCT)

Valuation Ratios
P/E Ratio -8
Price to Sales 13.7
Price to Book 9.5
Price to Tangible Book
Price to Cash Flow -10.9
Price to Free Cash Flow -10.7
Growth Rates
Sales Growth Rate 124.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -33.3%
Cap. Spend. - 3 Yr. Gr. Rate 14.9%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 81.7%
Total Debt to Equity 81.7%
Interest Coverage -27
Management Effectiveness
Return On Assets -43.2%
Ret/ On Assets - 3 Yr. Avg. -43.6%
Return On Total Capital -53%
Ret/ On T. Cap. - 3 Yr. Avg. -50.5%
Return On Equity -82.1%
Return On Equity - 3 Yr. Avg. -63.4%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -161.4%
EBITDA Margin - 3 Yr. Avg. -332.3%
Operating Margin -159%
Oper. Margin - 3 Yr. Avg. -336.8%
Pre-Tax Margin -171.1%
Pre-Tax Margin - 3 Yr. Avg. -340.8%
Net Profit Margin -171.1%
Net Profit Margin - 3 Yr. Avg. -335.5%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 1.4%
Payout Ratio 0%

PTCT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the PTCT stock intrinsic value calculation we used $194.392 million for the last fiscal year's total revenue generated by PTC Therapeutics. The default revenue input number comes from 0001 income statement of PTC Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our PTCT stock valuation model: a) initial revenue growth rate of 43.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for PTCT is calculated based on our internal credit rating of PTC Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of PTC Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of PTCT stock the variable cost ratio is equal to 52.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $176 million in the base year in the intrinsic value calculation for PTCT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.9% for PTC Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for PTC Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the PTCT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for PTCT are equal to 21.2%.

Life of production assets of 4.2 years is the average useful life of capital assets used in PTC Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for PTCT is equal to -12.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $156.437 million for PTC Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 46.446 million for PTC Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of PTC Therapeutics at the current share price and the inputted number of shares is $1.5 billion.

RELATED COMPANIES Price Int.Val. Rating
SRPT Sarepta Therap 118.96 2.96  str.sell
VRTX Vertex Pharmac 166.67 92.21  sell
FGEN FibroGen 40.36 2.04  str.sell
IONS Ionis Pharmace 51.67 6.10  str.sell
VYGR Voyager Therap 12.18 1.30  str.sell

COMPANY NEWS

▶ New Strong Sell Stocks for November 9th   [Nov-09-18 08:03AM  Zacks]
▶ Here's Why PTC Therapeutics Dropped 18% in October   [Nov-07-18 09:30PM  Motley Fool]
▶ PTC Therapeutics: 3Q Earnings Snapshot   [05:01AM  Associated Press]
▶ How Financially Strong Is PTC Therapeutics Inc (NASDAQ:PTCT)?   [Sep-13-18 12:43PM  Simply Wall St.]
▶ PTC Therapeutics: 2Q Earnings Snapshot   [04:52PM  Associated Press]
▶ What's Behind PTC Therapeutics' 10% Rally Today   [Jul-20-18 04:13PM  Motley Fool]
▶ Sarepta Therapeutics Could Be Onto Something Big   [Jun-25-18 02:21PM  Motley Fool]
▶ Is PTC Therapeutics Stock a Buy?   [01:47PM  Motley Fool]
▶ PTC Therapeutics (PTCT) Jumps: Stock Rises 7.2%   [Jun-21-18 08:44AM  Zacks]
▶ Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs   [Jun-20-18 03:35PM  Investor's Business Daily]
▶ PTC Therapeutics Inc (NASDAQ:PTCT) Is Expected To Breakeven   [Jun-18-18 09:09PM  Simply Wall St.]
▶ Small Caps And Blue Chips Lead; Stocks Attempt Breakouts   [12:08PM  Investor's Business Daily]
▶ PTC Therapeutics: 1Q Earnings Snapshot   [May-09-18 04:46PM  Associated Press]
▶ FIREFISH Transitions into Pivotal Phase   [Mar-15-18 08:00AM  PR Newswire]
▶ PTC Therapeutics posts 4Q profit   [Mar-06-18 04:21PM  Associated Press]
▶ PTC Therapeutics Q4 Earnings Preview   [08:05AM  Benzinga]
▶ [$$] Big Biotech Buys: Vericel, Achillion, PTC, Dicerna   [Mar-01-18 12:16PM  Barrons.com]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.